Stem Cell Therapy for Diabetes

Terapi Sel Punca untuk Diabetes

Diabetes is a disease characterized by chronic elevation of blood glucose levels, classified into type 1 and type 2.

In type 1 diabetes, an autoimmune disorder destroys insulin-producing cells, requiring lifelong insulin therapy. In type 2 diabetes, there is increased insulin resistance and decreased insulin production, which may necessitate insulin therapy as the disease progresses.

In both instances, treatment primarily focuses on blood sugar control, and the complete prevention of long-term complications remains challenging. Addressing this difficulty, regenerative therapies aimed at "fundamental repair" have gained attention in recent years.

Furthermore, stem cell therapy (MSC therapy), simultaneously targeting the restoration of insulin secretion and modulation of the immune environment, is anticipated as a promising new therapeutic option.

Stem Cell Therapy as Regenerative Therapy

Stem cell therapy is a new treatment method that aims for fundamental improvement of diabetes by restoring the function of insulin-producing cells and unleashing the body's healing power.

Conventional diabetes treatment has historically focused on a "management" approach to control blood sugar levels. However, with the growing need for "fundamental therapy" that restores the function of the pancreas itself, regenerative therapy is increasingly gaining attention.

Regenerative therapy is a medical discipline focused on repairing and regenerating damaged organ or tissue function by harnessing the body's intrinsic regenerative capabilities. In the context of diabetes, a range of regenerative techniques are currently under investigation with the objective of restoring the function of insulin-producing pancreatic beta-cells.

Among all options, stem cell therapy demonstrates the most promising results. Stem cells possess the unique ability to differentiate into various cell types or secrete essential factors, and are thus considered the cellular foundation for tissue regeneration.

A particular focus is on cells known as Mesenchymal Stem Cells (MSCs). MSCs can be extracted from tissues such as bone marrow, adipose tissue, and umbilical cord, and are characterized by high proliferative capacity as well as the ability to differentiate into various cell types (pluripotency).

In the field of diabetes, MSCs are expected to possess the following two characteristics:

  • Potential for differentiating into beta-cells and compensating for insufficient insulin secretion.
  • Secreting cytokines and growth factors to prepare the surrounding tissue environment and activate self-healing powers.

Notably, Wharton's Jelly Mesenchymal Stem Cells (WJ-MSCs) derived from the umbilical cord offer significant advantages due to their superior proliferative capacity and low immunogenicity. Extracted from newborn umbilical cords, these cells are exceptionally young and are reported to rarely elicit genetically-mediated rejection responses.

Additionally, autologous cell therapy may necessitate a surgical extraction procedure; however, allogeneic Wharton's jelly MSCs can be safely utilized, thereby significantly alleviating the physical burden on the body.

Consequently, MSC is not merely anticipated as a "replacement" therapy, but rather as one that "awakens the body's regenerative power," and is increasingly highlighted as a novel option for diabetes.

Key Point

  • In regenerative therapy for diabetes, the objective is to restore the function of insulin-producing pancreatic islet β-cells.
  • Mesengchymal Stem Cells (MSCs) are expected to have regenerative effects from both their pluripotentiality and secretory capabilities.
  • MSC has two functions: supplementing beta cells and modulating the tissue environment.
  • Wharton's jelly MSCs, derived from young umbilical cords, exhibit low immunogenicity and are safe for use even when donor-derived.
  • Its ability to be administered non-surgically and in a less invasive manner also makes it a therapeutic method that places minimal burden on the patient.

MSC-mediated Multifaceted Mechanism of Action

MSC is a therapeutic approach that can act simultaneously from various perspectives against various challenges in diabetes, including immune abnormalities, pancreatic dysfunction, and chronic inflammation.

The efficacy of MSC therapy extends beyond mere cell replacement. Ranging from the local pancreatic level to the systemic metabolic environment, "adjustment, restoration, and activation" can be achieved on a broad scale, effectively functioning as a 'multi-function switch' in the treatment of diabetes.

Here, we will explain three representative actions taken by MSC.

Immune Regulation (Autoimmune Suppressor)

In type 1 diabetes, pancreatic β-cells undergo autoimmune destruction. MSCs secrete anti-inflammatory cytokines such as IL-10 and TGF-β, which gently suppress excessive immune activation.

Specifically, it has been confirmed that this enhances regulatory T cells (Tregs) and suppresses the production of inflammatory T cells (Th1/Th17 system) and IFN-γ, and is expected to modulate the highly aggressive immune environment around the pancreatic islets.

This function acts as a control system that restrains an immune system prone to dysregulation.

Promotion of Tissue Repair and Regeneration

MSCs secrete growth factors such as VEGF and HGF, which promote the repair of damaged tissue and angiogenesis. In the pancreas, in addition to supporting the survival and functional maintenance of residual β-cells, reports also indicate the potential to promote the regeneration of new insulin-secreting β-cells.

In experiments, instances were also reported where MSCs differentiated into β-like cells possessing insulin-secretory capabilities. Conceptually, this can be likened to dispatching a repair team to a compromised cellular factory to facilitate its operational restoration.

Suppression of Inflammation and Optimization of the Metabolic Environment

In type 2 diabetes, chronic inflammation underlies insulin resistance. Anti-inflammatory cytokines secreted by MSCs (such as IL-10) suppress the production of excessive inflammatory cytokines like IL-6 and IL-1β.

Furthermore, by altering the composition of immune cells from pro-inflammatory to inhibitory types, the systemic metabolic environment shifts to a state where insulin functions effectively. This mechanism is akin to a "remediation of communication pathways" addressing a condition where whole-body metabolic signals are inadequately conveyed.

As previously explained, MSC therapy does not merely act on the pancreas as a specific site but also exerts systemic effects, influencing the immune system, inflammation, and metabolism. This capacity to simultaneously modulate multiple physiological circuits represents a significant advantage of stem cell therapy, unmatched by other therapeutic approaches.

Key Point

  • MSC exhibits activity in suppressing the autoimmune reactions that are problematic in type 1 diabetes.
  • Promoting the protection and regeneration of damaged pancreatic β-cells, contributing to the restoration of insulin secretory function.
  • By suppressing chronic inflammation and improving insulin resistance, it also acts on the metabolic environment of type 2 diabetes.
  • A key strength of MSCs is their ability to simultaneously target the immune system, pancreas, and metabolism at different levels.

Effects of Stem Cell Therapy According to Clinical Research

Effect on Type 1 Diabetes

MSC can lead to an increase in insulin secretion function and a reduction in insulin injections, with positive results especially reported in patients in the early phase of the disease.

In clinical trials of MSC therapy for type 1 diabetes, various studies have confirmed improvements in glycemic control and a reduction in insulin requirements. Notably, numerous instances have been observed where both C-peptide levels (a marker indicating endogenous insulin production) increased and HbA1c levels increased, and it has also demonstrated the potential for insulin injections to become unnecessary.

In fact, one study reported that approximately 20% of patients receiving MSC transplantation were able to discontinue insulin injections, and numerous other patients also experienced a significant reduction in their required dosage.

It has also been reported that efficacy varies depending on the type of stem cell. Specifically, umbilical cord-derived MSCs (Wharton's jelly MSCs) may demonstrate a greater reduction in HbA1c and an increase in C-peptide compared to those derived from bone marrow, and are superior in preserving pancreatic β-cell function.

Reports also indicate long-term effectiveness, with approximately 80% of patients undergoing MSC therapy maintaining stable HbA1c levels for over 3 years. Typically, glycemic control tends to worsen over time, making this a notable finding. A slower decline in C-peptide was also observed, which is expected to contribute to the preservation of pancreatic function.

Furthermore, an analysis evaluating multiple clinical trials also concluded that MSC is likely beneficial in reducing insulin requirements and stabilizing glycemic control.

Key Point

  • MSC injections have been reported to increase C-peptide and increase HbA1c.
  • Efficacy is indicated, with approximately 20% of patients no longer requiring insulin injections.
  • MSCs derived from the umbilical cord may have higher efficacy than those derived from bone marrow.
  • There are also instances of stable HbA1c maintenance for over three years, and the long-term effects are garnering significant attention.
  • Collectively, numerous clinical studies demonstrate a reduction in insulin requirements and improved glycemic control.

Effects on Type 2 Diabetes

In type 2 diabetes, too, MSC therapy has been shown to have potential in helping to stabilize blood sugar, reducing insulin resistance and inflammation, and suppressing the risk of complications.

In studies focused on type 2 diabetes, there is a growing number of reports detailing enhanced glycemic control through MSC injections. Specifically, in patients with severe conditions necessitating insulin, the restoration of insulin secretion and stabilization of blood glucose have been confirmed.

In one clinical trial, following the injection of placenta-derived MSCs, the required insulin dose was halved, and an increase in C-peptide levels was also confirmed. In a separate trial, utilizing umbilical cord-derived MSCs, 41% of patients were able to discontinue insulin injections, and it was reported that 94% experienced a reduction in insulin use.

Furthermore, improvements were also observed in immune and inflammatory markers. Following MSC injection, inflammatory T-cell activity was suppressed, and the levels of inflammatory cytokines such as IL-6 and IL-1β also decreased. These changes are believed to contribute to improved insulin resistance.

Furthermore, a suppressive effect on the risk of complication development has also been reported. In studies involving umbilical cord-derived Mesenchymal Stem Cells (MSCs), 30% of patients no longer required insulin treatment for over 1 year post-therapy, and fewer complications such as nephropathy and neuropathy were reported.

Given its beneficial effects not only on glycemic control but also on overall systemic metabolic health and quality of life, MSC therapy is garnering attention as a novel therapeutic option for diabetes.

Key Point

  • In cases of severe Type 2 diabetes, there have been instances of significant reduction in insulin use.
  • Elevations in C-peptide and HbA1c were reported, and a beneficial effect on glycemic control was demonstrated.
  • Suppression of inflammation and increased insulin resistance have been confirmed.
  • Mitigation of complication risks and long-term blood sugar stabilization are also anticipated.
  • By targeting pancreatic, immune, and metabolic pathways, it has garnered attention as a multifunctional therapy.

Safety and Risks of Side Effects of Stem Cell Therapy

MSC therapy is a highly safe treatment method confirmed for diabetes. Reports of severe side effects are very rare, and because the burden on the body is light, it is increasingly gaining attention.

When introducing a new therapeutic method, its safety is the paramount consideration. Numerous clinical trials involving mesenchymal stem cell (MSC) treatments have reported virtually no severe adverse events or complications. Both domestic and international research has established that MSC injections in diabetic patients demonstrate a high safety profile.

Significantly, Wharton's jelly-derived MSCs (WJ-MSCs) utilized in our facility have not reported adverse events in actual clinical applications, thereby validating their high safety profile. Furthermore, a recent meta-analysis also evaluated MSC therapy for type 1 and type 2 diabetes as a treatment modality demonstrating both efficacy and safety.

Underlying this safety is the low immunogenicity of MSCs. Typically, when allogeneic cells are introduced into the body, an immune rejection reaction occurs. However, MSCs possess the characteristic of low Human Leukocyte Antigen (HLA) expression on their cell surface, making them difficult for the immune system to recognize. Consequently, even when using donor-derived cells, injections can be performed safely without the need for specific immunosuppressive agents.

Furthermore, MSC therapy is also appreciated for its low systemic burden. This treatment is primarily administered via intravenous infusion, although local injections are also possible, without the invasiveness typically associated with general surgery. In many cases, the procedure can be completed in an outpatient setting, thus alleviating the patient's burden as it does not necessitate hospitalization.

From this perspective, stem cell therapy is an advanced therapy for diabetes that, while characterized by rare side effects and low invasiveness, merits significant consideration.

Key Point

  • Serious side effects or adverse events are rarely reported in MSC therapy.
  • Umbilical cord-derived MSCs demonstrate a notably superior track record in terms of safety and stability.
  • Due to their low immunogenicity and resistance to rejection, MSCs can be administered without immunosuppressive agents.
  • Infusion administration is a minimally invasive treatment, garnering interest as an outpatient therapy.
  • It is anticipated that future expanded introduction will be as a treatment option combining safety and practicality.

The Future of Diabetes Treatment

Stem cell therapy is a regenerative therapy aimed at the fundamental improvement of diabetes by simultaneously promoting pancreatic islet cell regeneration and immune normalization.

Domestic and international research has reported positive results concerning both safety and efficacy, with steady progress towards future practical implementation. The realization of stem cell-based treatments that stabilize blood sugar without insulin dependence and progressively prevent complication development is drawing increasingly near.

Given that it is a chronic illness, new options aimed at fundamental improvement will offer hope.

Contact Us
Literatur Referensi